trending Market Intelligence /marketintelligence/en/news-insights/trending/oos_fXClMg8awWVCvWNzJQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Boston Scientific, BTG £3.3B merger cleared in 3 countries

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Boston Scientific, BTG £3.3B merger cleared in 3 countries

BTG PLC said its £3.3 billion acquisition by Boston Scientific Corp. received antitrust clearance in the U.S., Spain and Austria.

The proposed transaction was cleared by the U.S. Federal Trade Commission, Spanish regulator CNMC and the Federal Competition Authority of Austria.

The acquisition remains subject to closing conditions, including court approval, with the hearing scheduled on Aug. 15.

Marlborough, Mass.-based medical-device maker Boston Scientific announced in November 2018 that it was acquiring London's BTG, which develops and sells drugs for treating cancer and vascular diseases, for 840 pence per share through a scheme of arrangement.

The deal is expected to become effective Aug. 19. Upon completion, BTG's shares will be delisted from the London Stock Exchange on Aug. 20.